World · Daily Terminal(Alliance News) - GSK PLC on Tuesday said a phase 2 probe of its mRNA flu vaccine candidate showed positive results and that phase 3 trials will start this month. The London-based pharmaceuticals company said its flu vaccine candidate showed higher immune responses against all flu types compared with currently licensed vaccines, both at a standard dose for younger adults and at a higher dose for older adults. GSK said the vaccine candidate was "generally well tolerated".
The product will now advance to phase 3 trials. The vaccine candidate uses messenger RNA technology and is designed to target the two molecules responsible for the spread of flu viruses, as opposed to currently licensed flu vaccines, which primarily target only one of them, GSK explained. The company added that there is growing evidence to suggest targeting both could improve protection, reduce illness severity and limit transmission.
Sanjay Gurunathan, head of vaccines & infectious diseases research & development at GSK, said: "With one billion flu cases worldwide each year and up to 650,000 deaths there is a need for next generation vaccine approaches." GSK shares rose 0.2% to 1,858.00 pence in London. By Camilla Borri, Alliance News reporter Comments and questions to newsroom@alliancenews.com Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site.
The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content.
The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Source: Morningstar
